Gilead Sciences, Inc. $GILD Shares Sold by WealthBridge Investment Counsel Inc.

Key Points

• WealthBridge Investment Counsel Inc. reduced its holdings in Gilead Sciences by 6.4% in the 2nd quarter, now owning 64,955 shares valued at approximately $7.2 million.
• Gilead Sciences reported a quarterly earnings of $2.01 EPS, surpassing analyst estimates, with revenues reaching $7.08 billion for the quarter.
• The company declared a quarterly dividend of $0.79 per share, representing an annualized payout of $3.16 and a yield of 2.8%.

WealthBridge Investment Counsel Inc. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 64,955 shares of the biopharmaceutical company's stock after selling 4,450 shares during the quarter. Gilead Sciences makes up about 2.3% of WealthBridge Investment Counsel Inc.'s holdings, making the stock its 17th biggest holding. WealthBridge Investment Counsel Inc.'s holdings in Gilead Sciences were worth $7,202,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Argentarii LLC lifted its position in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after purchasing an additional 99 shares during the period. Peak Financial Advisors LLC grew its position in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after acquiring an additional 100 shares in the last quarter. Perkins Coie Trust Co boosted its holdings in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares during the period. Investment Research & Advisory Group Inc. increased its position in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Lodestar Private Asset Management LLC lifted its position in Gilead Sciences by 3.6% during the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock worth $318,000 after acquiring an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

GILD opened at $114.09 on Friday. The stock has a market capitalization of $141.56 billion, a PE ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $81.83 and a 1 year high of $121.83. The company's 50 day simple moving average is $114.10 and its 200 day simple moving average is $110.06.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Analyst Ratings Changes

A number of research analysts have recently commented on GILD shares. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Finally, Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $117.17.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at $12,855,329.01. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $9,390,030. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.